Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2025)

Historic Gross Profit for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to $110.4 million.

  • Tarsus Pharmaceuticals' Gross Profit rose 14598.45% to $110.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.4 million, marking a year-over-year increase of 18332.19%. This contributed to the annual value of $170.1 million for FY2024, which is 97308.57% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Gross Profit of $110.4 million as of Q3 2025, which was up 14598.45% from $96.4 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Gross Profit's 5-year high stood at $110.4 million during Q3 2025, with a 5-year trough of $362000.0 in Q4 2021.
  • Moreover, its 5-year median value for Gross Profit was $21.3 million (2021), whereas its average is $32.1 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Gross Profit tumbled by 9842.54% in 2022 and then skyrocketed by 290374.83% in 2024.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Gross Profit stood at $362000.0 in 2021, then skyrocketed by 2551.93% to $9.6 million in 2022, then rose by 23.54% to $11.9 million in 2023, then skyrocketed by 418.4% to $61.5 million in 2024, then soared by 79.55% to $110.4 million in 2025.
  • Its last three reported values are $110.4 million in Q3 2025, $96.4 million for Q2 2025, and $73.1 million during Q1 2025.